California State Teachers Retirement System raised its position in shares of Genomic Health Inc. (NASDAQ:GHDX) by 4.0% during the second quarter, Holdings Channel reports. The institutional investor owned 39,167 shares of the company’s stock after buying an additional 1,510 shares during the period. California State Teachers Retirement System owned 0.12% of Genomic Health worth $1,014,000 at the end of the most recent reporting period.
A number of other large investors have also bought and sold shares of the stock. HBK Investments L P acquired a new stake in Genomic Health during the first quarter worth approximately $886,000. Kimelman & Baird LLC increased its stake in Genomic Health by 2.3% in the first quarter. Kimelman & Baird LLC now owns 21,940 shares of the company’s stock worth $543,000 after buying an additional 500 shares in the last quarter. Loomis Sayles & Co. L P acquired a new stake in Genomic Health during the first quarter worth approximately $15,639,000. Geode Capital Management LLC increased its stake in Genomic Health by 13.4% in the first quarter. Geode Capital Management LLC now owns 158,078 shares of the company’s stock worth $3,915,000 after buying an additional 18,645 shares in the last quarter. Finally, BlackRock Inc. increased its stake in Genomic Health by 1.6% in the first quarter. BlackRock Inc. now owns 46,991 shares of the company’s stock worth $1,164,000 after buying an additional 719 shares in the last quarter. Institutional investors own 88.92% of the company’s stock.
Shares of Genomic Health Inc. (NASDAQ:GHDX) traded up 0.66% during midday trading on Tuesday, reaching $29.19. The company’s stock had a trading volume of 107,221 shares. Genomic Health Inc. has a 52 week low of $20.05 and a 52 week high of $35.79. The firm’s market capitalization is $973.37 million. The firm’s 50 day moving average is $27.55 and its 200 day moving average is $26.81.
Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.18) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.18). Genomic Health had a negative return on equity of 21.02% and a negative net margin of 8.84%. The business had revenue of $81.97 million for the quarter, compared to analysts’ expectations of $81.27 million. During the same quarter last year, the firm earned ($0.29) earnings per share. The business’s revenue was up 16.1% on a year-over-year basis. Equities analysts forecast that Genomic Health Inc. will post ($0.47) EPS for the current fiscal year.
A number of equities research analysts have commented on GHDX shares. Zacks Investment Research downgraded Genomic Health from a “hold” rating to a “sell” rating in a research report on Tuesday, July 5th. Jefferies Group boosted their price objective on Genomic Health from $25.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, August 17th. Canaccord Genuity reiterated a “buy” rating and issued a $38.00 price objective on shares of Genomic Health in a report on Friday, August 5th. Leerink Swann reiterated a “buy” rating on shares of Genomic Health in a report on Tuesday, June 21st. Finally, Bank of America Corp. set a $28.00 price objective on Genomic Health and gave the company a “sell” rating in a report on Wednesday, August 3rd. Three analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $32.44.
In other news, Director Felix Baker bought 100,000 shares of Genomic Health stock in a transaction that occurred on Monday, August 15th. The shares were purchased at an average price of $27.02 per share, for a total transaction of $2,702,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO G Bradley Cole sold 5,000 shares of Genomic Health stock in a transaction on Wednesday, July 6th. The shares were sold at an average price of $26.64, for a total value of $133,200.00. Following the completion of the transaction, the chief operating officer now owns 40,426 shares in the company, valued at approximately $1,076,948.64. The disclosure for this sale can be found here. Insiders own 47.00% of the company’s stock.
About Genomic Health
Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.
Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health Inc. (NASDAQ:GHDX).
Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.